35 results on '"Kudo, K."'
Search Results
2. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer
3. SRPX2 IS A NOVEL CHONDROITIN SULFATE PROTEOGLYCAN THAT IS OVEREXPRESSED IN GASTROINTESTINAL CANCER
4. A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
5. Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
6. A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401
7. Serum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer
8. Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients
9. A phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
10. Impact of immune checkpoint inhibitors on subsequent chemotherapy
11. Phase I/II trial of weekly nab-paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations. (OLCSG1303)
12. 521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
13. 1807P - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401
14. 1525P - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
15. 1473P - Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients
16. 1200P - Serum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer
17. 453P Development of skin rash within the first week is a potential surrogate marker of effect in afatinib for EGFR mutant NSCLC: Okayama Lung Cancer Study Group Experience
18. 439P - Impact of immune checkpoint inhibitors on subsequent chemotherapy
19. 426P - A phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
20. 1368P - Phase I/II trial of weekly nab-paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations. (OLCSG1303)
21. Epidermal Growth Factor Receptor Signaling Conferred Acquired Crizotinib Resistance to a Non-Small Cell Lung Cancer Cell Line Harboring the Slc34A2-Ros1 Fusion Gene
22. Acquired Resistance to a New Alk Inhibitor, Alectinib in Lung Cancer
23. Subcutaneous Implantation Type Central Veins Port (CV Port) Management in Patients with Malignant Tumor
24. Usefulness of the Treatment Algorithm for Oxaliplatin-Induced Peripheral Neuropathy
25. Phase I Study of Patritumab (U3-1287) in Combination with Erlotinib in Japanese Patients with Non-Small Cell Lung Cancer
26. Prospective Feasibility Study of Cisplatin-Based Chemotherapy with a Short-Term Small Amount of Hydration Method in Advanced Lung Cancer
27. Difference in Incidence and Pattern of Salvage Treatment After Failure to 1ST-Line EGFR-TKI Therapy and Standard Cytotoxic Chemotherapy in Patients with EGFR-Mutant Advanced NSCLC: Okayama Lung Cancer Study Group Experience
28. Phase II Trial of Bevacizumab Plus Docetaxel in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer
29. ALK and EGFR Mutation Analysis in a Phase II Trial of Cisplatin/Pemetrexed in Japanese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
30. 1584P - Acquired Resistance to a New Alk Inhibitor, Alectinib in Lung Cancer
31. 152P - Epidermal Growth Factor Receptor Signaling Conferred Acquired Crizotinib Resistance to a Non-Small Cell Lung Cancer Cell Line Harboring the Slc34A2-Ros1 Fusion Gene
32. 669P A retrospective observational study on the efficacy of local ablative therapy for oligoprogression in non-small cell lung cancer patients who responded to immunotherapy combined chemotherapy.
33. O2–096PHASE I STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH ERLOTINIB IN JAPANESE PATIENTS WITH NON-SMALL CELL LUNG CANCER.
34. P2–041USEFULNESS OF THE TREATMENT ALGORITHM FOR OXALIPLATIN-INDUCED PERIPHERAL NEUROPATHY.
35. P3–112SUBCUTANEOUS IMPLANTATION TYPE CENTRAL VEINS PORT (CV PORT) MANAGEMENT IN PATIENTS WITH MALIGNANT TUMOR.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.